Breaking News Instant updates and real-time market news.

PRNB

Principia Biopharma

$37.30 /

+0.86 (+2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07

Principia Biopharma announces 'consistent positive data' for PRN1008

Principia Biopharma announced "consistent positive data" from an ongoing Phase 1/2 trial of its investigational treatment, PRN1008, in 31 highly treatment-resistant and refractory patients with immune thrombocytopenia. This analysis includes 31 adult patients who had a median baseline platelet count of 13,000 microliter. The patient population for this analysis had a median duration of disease of 7.8 years and a median of six prior ITP treatments. Oral PRN1008 starting doses were 200mg once daily, 400mg once daily, 300mg twice daily, and 400mg twice daily, with intra-patient dose escalation allowed every four weeks, and with the trial having a current median treatment duration of 12 weeks. "We are very encouraged by the data so far and pleased to see meaningful clinical responses and quick onset in this highly pre-treated patient population. We are also pleased to observe that this investigational drug so far has not seen the typical BTK class side effects," said Dr. Kuter, the trial's principal investigator. "As we continue to execute on our PRN1008 and BTK franchise strategy, these data represent yet another validation of our scientific platform as well as demonstration of our ability to develop oral therapies without compromising the desired efficacy or a favorable tolerability profile. We now have proof of concept in two immune mediated diseases," said Martin Babler, Principia CEO.

PRNB Principia Biopharma
$37.30 /

+0.86 (+2.36%)

10/10/19 H.C. Wainwright
Principia announces 'positive' data from Phase 2 trial, says H.C. Wainwright
10/10/19 Stifel
Principia Biopharma price target raised to $51 from $45 at Stifel
10/02/19 Stifel
Stifel remains buyer of Principia Biopharma into Q4 data readouts
07/01/19 H.C. Wainwright
Principia Biopharma initiated with a Buy at H.C. Wainwright

TODAY'S FREE FLY STORIES

Hot Stocks
uniQure presents new preclinical data on AMT-130 » 07:55
02/27/20
02/27
07:55
02/27/20
07:55
QURE

uniQure

$53.57 /

-0.96 (-1.76%)

uniQure announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Aqua America to host investor day » 07:55
02/27/20
02/27
07:55
02/27/20
07:55
WTR

Aqua America

$0.00 /

+ (+0.00%)

Investor day to be held…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Crane to host investor day » 07:55
02/27/20
02/27
07:55
02/27/20
07:55
CR

Crane

$74.85 /

-2.39 (-3.09%)

Investor day to be held…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Teladoc price target raised to $130 from $100 at Baird » 07:54
02/27/20
02/27
07:54
02/27/20
07:54
TDOC

Teladoc

$116.89 /

-1.55 (-1.31%)

Baird analyst Matthew…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Athenex provides outlook on upcoming milestones » 07:53
02/27/20
02/27
07:53
02/27/20
07:53
ATNX

Athenex

$12.26 /

-0.11 (-0.89%)

Outlook and Upcoming…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Athenex expects cash, cash equivalents to fund operations into 1Q21 » 07:52
02/27/20
02/27
07:52
02/27/20
07:52
ATNX

Athenex

$12.26 /

-0.11 (-0.89%)

At December 31, 2019, the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Upwork sees Q1 revenue $81.5M-$82.5M, consensus $83.46M » 07:51
02/27/20
02/27
07:51
02/27/20
07:51
UPWK

Upwork

$8.13 /

-0.19 (-2.28%)

In yesterday's…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Anaplan sinks 26%, or $15.9, to $42.80 following Q4 results  07:51
02/27/20
02/27
07:51
02/27/20
07:51
PLAN

Anaplan

$57.97 /

+0.87 (+1.52%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Anaplan Chief Growth Officer Mark Anderson stepping down » 07:51
02/27/20
02/27
07:51
02/27/20
07:51
PLAN

Anaplan

$57.97 /

+0.87 (+1.52%)

Anaplan announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Esperion expects U.S. commercial launch of NEXLETOL March 30 » 07:51
02/27/20
02/27
07:51
02/27/20
07:51
ESPR

Esperion

$57.06 /

-2.91 (-4.85%)

Three data presentations…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Esperion expects potential ROW development in April » 07:50
02/27/20
02/27
07:50
02/27/20
07:50
ESPR

Esperion

$57.06 /

-2.91 (-4.85%)

European Commission…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
TJX price target raised to $75 from $70 at Guggenheim » 07:50
02/27/20
02/27
07:50
02/27/20
07:50
TJX

TJX

$64.05 /

+4.28 (+7.16%)

, ROST

Ross Stores

$119.24 /

+2.52 (+2.16%)

, BURL

Burlington Stores

$234.06 /

-1.305 (-0.55%)

Guggenheim analyst Robert…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Etsy price target raised to $75 from $70 at Loop Capital » 07:50
02/27/20
02/27
07:50
02/27/20
07:50
ETSY

Etsy

$50.64 /

+0.73 (+1.46%)

Loop Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Esperion expects U.S. commercial launch of NEXLIZET in July » 07:49
02/27/20
02/27
07:49
02/27/20
07:49
ESPR

Esperion

$57.06 /

-2.91 (-4.85%)

Sees $150M milestone…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Esperion sees cash sufficient to fund operations through profitability » 07:48
02/27/20
02/27
07:48
02/27/20
07:48
ESPR

Esperion

$57.06 /

-2.91 (-4.85%)

Esperion expects $175…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Nexstar price target raised to $150 from $142 at Guggenheim » 07:47
02/27/20
02/27
07:47
02/27/20
07:47
NXST

Nexstar

$107.14 /

-6.79 (-5.96%)

Guggenheim analyst Curry…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Credit Suisse anticipates quick recovery for Microsoft given strong end demand » 07:46
02/27/20
02/27
07:46
02/27/20
07:46
MSFT

Microsoft

$170.20 /

+2.14 (+1.27%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
BioLineRx granted patent by USPTO for Motixafortide » 07:46
02/27/20
02/27
07:46
02/27/20
07:46
BLRX

BioLineRx

$1.78 /

-0.11 (-5.82%)

BioLineRx announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Emcor sees FY20 EPS $5.60-$6.30, consensus $6.00 » 07:46
02/27/20
02/27
07:46
02/27/20
07:46
EME

Emcor

$79.42 /

-1.2 (-1.49%)

Sees FY20 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Rite Aid upgraded to Neutral ahead of analyst day at Guggenheim » 07:45
02/27/20
02/27
07:45
02/27/20
07:45
RAD

Rite Aid

$12.99 /

-0.51 (-3.78%)

Guggenheim analyst Glen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
INDIVA, Lift & Co. release branded CannSell education module » 07:45
02/27/20
02/27
07:45
02/27/20
07:45
NDVAF

INDIVA

$0.00 /

+ (+0.00%)

Indiva and Lift & Co.…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
Treasury Market Outlook: Treasuries are rallying sharply and the curve is steepening » 07:45
02/27/20
02/27
07:45
02/27/20
07:45

Treasury Market Outlook:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Recommendations
Square price target raised to $93 from $73 at Guggenheim » 07:44
02/27/20
02/27
07:44
02/27/20
07:44
SQ

Square

$76.63 /

-0.38 (-0.49%)

Guggenheim analyst Jeff…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Emcor reports Q4 EPS $1.54, consensus $1.50 » 07:44
02/27/20
02/27
07:44
02/27/20
07:44
EME

Emcor

$79.42 /

-1.2 (-1.49%)

Reports Q4 revenue $2.4B,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Great Elm Capital appoints Jason Reese, Eric Scheyer to board of directors » 07:44
02/27/20
02/27
07:44
02/27/20
07:44
GEC

Great Elm Capital

$2.93 /

+ (+0.00%)

Great Elm Capital Group…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.